Compare EFOI & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOI | OGEN |
|---|---|---|
| Founded | 1985 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 3.6M |
| IPO Year | 1994 | N/A |
| Metric | EFOI | OGEN |
|---|---|---|
| Price | $2.59 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.6K | ★ 84.3K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,863,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $0.82 |
| 52 Week High | $3.56 | $18.90 |
| Indicator | EFOI | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 40.04 |
| Support Level | $1.93 | $0.85 |
| Resistance Level | $2.14 | $1.00 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 59.34 | 33.64 |
Energy Focus Inc engages in the design, development, manufacturing, marketing, and sale of energy-efficient lighting systems and controls. The company serves the military maritime market and general commercial markets. Its product offerings include Military maritime LED lighting products such as military intelligible, globe lights, berth lights, and military fixtures and Commercial products such as LED fixtures and panels, LED down-lights, LED dock lights, and LED retrofit kits. Geographically, it operates in the United States and other countries. Its products include commercial products and MMM products. The company generates a majority of its sales from Military maritime products in the United States.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.